NCT06650488

Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 300 (estimated)
• Sponsor: Todd C. Lee MD MPH FIDSA · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking aspirin for secondary prevention of cardiovascular events. We will randomize patients to continue their aspirin or change clopidogrel which is also approved for secondary prevention. Unlike aspirin, clopidogrel may have activity against S. aureus. We wish to determine if changing to clopidogrel will improve outcomes in S. aureus bacteremia in people who otherwise would have a reason to be taking it. This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119). If positive, this study will support a Phase 3 RCT in people who do not currently have an indication for clopidogrel.

Conditions

• Staphylococcus Aureus Endocarditis
• Staphylococcus Aureus Septicemia
• Staphylococcus Aureus Bloodstream Infection

Interventions

Type	Name	Description
DRUG	Clopidogrel	Patients will change from aspirin to clopidogrel (without loading dose)
DRUG	Aspirin	Patients will continue their existing aspirin.

Timeline

• Start date: 2026-01-15
• Primary completion: 2030-01-01
• Completion: 2030-01-01
• First posted: 2024-10-21
• Last updated: 2026-03-20

Locations

1 site across 1 country: Canada